Expert Insights

At the 2022 San Antonio Breast Cancer Symposium, Sara Tolaney, MD, MPH, makes the case that HER2 low should not be considered a new breast cancer subtype.

Javid Moslehi, MD, discusses the cardiovascular risks associated with utilization of BTK inhibitors for patients with CLL and outlines best practices for managing these adverse events.

Lyudmila Bazhenova, MD, reviews the treatment options for BRAF mutations in lung cancer, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.

Edward Garon, MD, discusses the treatment of patients with non-small cell lung cancer and a PD-L1 expression of ≥50%, a topic he debated at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.